The suit escalates a battle between Pfizer and Novo Nordisk over Metsera, whose obesity pipeline could yield new competitors ...

(Reuters) -Pfizer Inc said on Monday it has filed a second lawsuit against Metsera and its controlling shareholders, as well ...

Lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by killing ...

Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo ...

Pfizer insists that Novo Nordisk’s unsolicited offer to acquire Metsera is an effort from the Danish pharma to “suppress ...

This second lawsuit represents an escalation of Pfizer’s efforts to block the Danish drug giant’s $9bn offer for Metsera, ...

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales ...

Pfizer has followed through on its threats, filing a lawsuit against both Metsera and Novo Nordisk during a M&A bidding war ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted ...

Denmark's Novo Nordisk launched a rival bid for U.S. obesity biotech firm Metsera on Thursday, hijacking an offer from Pfizer ...

Novo Nordisk has submitted an unsolicited bid to buy obesity biotech Metsera out from under Pfizer, offering $6 billion ...

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a ...